参考文献/References:
[1] Kirchhoff C,Habben I,Ivell R,et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors[J]. Biol Reprod,1991,45(2):350-357.
[2] Sharp JA,Lefèvre C,Nicholas KR. Molecular evolution of monotreme and marsupial whey acidic protein genes[J]. Evol Dev,2007,9(4):378-392.
[3] Galgano MT,Hampton GM,Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues[J]. Mod Pathol,2006,19(6):847-853.
[4] Bingle L,Cross SS,High AS,et al. WFDC2(HE4):a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung[J]. Respir Res,2006, 7(1):61.
[5] Schummer M,Ng WV,Bumgarner RE,et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas[J]. Gene,1999,238(2):375-385.
[6] Drapkin R,von Horsten HH,Lin Y,et al. Human epididymis protein 4(HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J]. Cancer Res,2005,65(6):2162-2169.
[7] Lu R,Sun X,Xiao R,et al. Human epididymis protein 4(HE4) plays a key role in ovarian cancer cell adhesion and motility[J]. Biochem Biophys Res Commun,2012,419(2):274-280.
[8] Moore RG,Brown AK,Miller MC,et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol,2008,108(2):402-408.
[9] Moore RG,Miller MC,Disilvestro P,et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass[J]. Obstet Gynecol,2011,118(2 Pt 1):280-288.
[10] LeBleu VS,Teng Y,O’Connell JT,et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis[J]. Nat Med,2013,19(2):227-231.
[11] Yamamoto M,Hanatani S,Araki S,et al. HE4 predicts progressive fibrosis and cardiovascular events in patients with dilated cardiomyopathy[J]. J Am Heart Assoc,2021,10(15):e021069.
[12] de Boer RA,Cao Q,Postmus D,et al. The WAP four-disulfide core domain protein HE4:a novel biomarker for heart failure[J]. JACC Heart Fail,2013,1(2):164-169.
[13]Tang Y,Hu Z,Liu Z,et al. HE4 serum levels are associated with poor prognosis in patients with acute heart failure combined with chronic kidney disease[J]. Int J Gen Med,2024,17:1273-1280.
[14] Piek A,Meijers WC,Schroten NF,et al. HE4 serum levels are associated with heart failure severity in patients with chronic heart failure[J]. J Card Fail,2017,23(1):12-19.
[15] Jin Q,Tang Y,Liu Z,et al. Serum human epididymis protein 4 level as a predictor of clinical worsening in idiopathic pulmonary arterial hypertension:a pilot study[J]. BMC Cardiovasc Disord,2020,20(1):175.
[16] Tang Y,Huo X,Liu J,et al. MicroRNA-325-3p targets human epididymis protein 4 to relieve right ventricular fibrosis in rats with pulmonary arterial hypertension[J]. Cardiovasc Ther,2022,2022:4382999.
[17] Liu LCY,Valente MAE,Postmus D,et al. Identifying subpopulations with distinct response to treatment using plasma biomarkers in acute heart failure:results from the PROTECT trial:differential response in acute heart failure[J]. Cardiovasc Drugs Ther,2017,31(3):281-293.
[18] Kilci H,Alt?nbilek E,?etinkal G,et al. Relation of a novel fibrosis marker and post-myocardial infarction left ventricular ejection fraction in revascularized patients[J]. Biomark Med,2021,15(17):1651-1658.
[19]Yan Q,Wu L,Song J,et al. Serum human epididymis protein 4 as a prognostic predictor of new-onset heart failure among women after acute coronary syndrome:a single-center retrospective study[J]. Cardiology,2023,148(3):230-238.
[20] Tang Y,Wang Y,Xu X,et al. Human epididymis protein 4:a novel predictor of ischemic cardiomyopathy[J]. BMC Cardiovasc Disord,2021,21(1):511.
[21] Ogata F,Hanatani S,Nakashima N,et al. Human epididymis protein 4 is a useful predictor of post-operative prognosis in patients with severe aortic stenosis[J]. ESC Heart Fail,2024,11(5):2924-2932.
[22] Luo HL,He C,Xue H,et al. Serum human epididymis protein 4 is associated with disease severity in patients with IgA nephropathy[J]. Clin Biochem,2024,123:110701.
[23] Huang X,Guo X,Yan G,et al. Dapagliflozin attenuates contrast-induced acute kidney injury by regulating the HIF-1α/HE4/NF-κB pathway[J]. J Cardiovasc Pharmacol,2022,79(6):904-913.
[24] Yang Z,Zhang Z,Qin B,et al. Human epididymis protein 4:a novel biomarker for lupus nephritis and chronic kidney disease in systemic lupus erythematosus[J]. J Clin Lab Anal,2016,30(6):897-904.
[25] Ren Y,Xie J,Lin F,et al. Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus:a prospective cohort study [J]. Int Immunopharmacol,2018,60:189-193.
[26] Li L,Xu H,Le Y,et al. Elevated serum levels of human epididymis protein 4 in adult patients with proliferative lupus nephritis[J]. Front Immunol,2023,14:1179986.
[27] Li Y,Zhong X,Yang F,et al. Silencing HE4 alleviates the renal fibrosis in lupus nephritis mice by regulating the C3/MMPs/prss axis[J]. Naunyn Schmiedebergs Arch Pharmacol,2024,397(7):4823-4831.
[28] Zhang M,Zhao B,Xie J,et al. Serum human epididymis protein 4 is associated with renal function and diabetic kidney disease in patients with type 2 diabetes mellitus[J]. Biomed Res Int,2019,2019:4831459.
[29] Nagy B Jr,Krasznai ZT,Balla H,et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease[J]. Ann Clin Biochem,2012,49(Pt 4):377-380.
[30] Wan J,Wang Y,Cai G,et al. Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease[J]. Oncotarget,2016,7(42):67748-67759.
[31] Huang Y,Jiang H,Zhu L. Human epididymis protein 4 as an indicator of acute heart failure in patients with chronic kidney disease[J]. Lab Med,2020,51(2):169-175.
[32] Luo J,Wang F,Wan J,et al. Serum human epididymis secretory protein 4 as a potential biomarker of renal fibrosis in kidney transplantation recipients[J]. Clin Chim Acta,2018,483:216-221.
[33] Tajima S,Fu R,Shigematsu T,et al. Urinary human epididymis secretory protein 4 as a useful biomarker for subclinical acute rejection three months after kidney transplantation[J]. Int J Mol Sci,2019,20(19):4699.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(12):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(12):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(12):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(12):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(12):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(12):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(12):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]